{
    "data": [
        {
            "id": "4559168",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-18T17:50:00-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1059134930/image_1059134930.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: Recovery Seems To Be A Mirage",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44381",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "421074",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4559168-nektar-therapeutics-recovery-seems-to-be-a-mirage"
            }
        },
        {
            "id": "4523849",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-17T12:51:03-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1190354350/image_1190354350.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar: Time To Abandon Ship",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "382961",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4523849-nektar-stock-time-abandon-ship"
            }
        },
        {
            "id": "4499718",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-04T16:38:48-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1312699932/image_1312699932.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "368346",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4499718-after-a-high-profile-failure-in-melanoma-nektar-therapeutics-value-shifts-to-its-early-stage-pipeline"
            }
        },
        {
            "id": "4481656",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-26T03:02:40-05:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/538866580/image_538866580.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: Beaten Down By 2021",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "358603",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4481656-nektar-therapeutics-nktr-stock-beaten-down-2021"
            }
        }
    ]
}